Diabetes Drug
GLP-1 agonists have transformed diabetes care. What's next in the pipeline?
A (Endocrinologist): The dual agonists (tirzepatide - GLP-1/GIP) and triple agonists (retatrutide - GLP-1/GIP/glucagon) are even more potent. Tirzepatide achieves A1c reductions of 2.0-2.5% and weight loss of 15-20% in clinical trials. Retatrutide showed 24% weight loss at 48 weeks in Phase 2. Side effects (nausea, vomiting, gastroparesis) are dose-limiting.
B (Pharmacist - Clinical): The shortage crisis is real and ethically fraught. Off-label prescribing for cosmetic weight loss to the "worried well" has created scarcity for patients with type 2 diabetes who need these drugs for glucose control. We need tiered access, dedicated manufacturing lines for diabetes indications, or prior authorization requirements.
C (Payer/Insurer): At $1,000+ per month per patient, these drugs will bankrupt Medicare and Medicaid. The Congressional Budget Office projects that if just 10% of obese adults take GLP-1s, it would cost $350 billion over 10 years.…